Executive Summary
Veeva Systems delivered a solid QQ4 2025 performance, underscored by durable top-line growth and healthy profitability. Revenue reached $720.9 million, up 14.3% YoY and 3.1% QoQ, supported by a high gross margin of 74.9% and an operating margin of 26.1%. Net income of $195.6 million produced EPS of $1.20 (diluted $1.18). The quarter also showcased strong cash generation and an excellent liquidity position, with cash and short-term investments totaling roughly $5.15 billion and a net cash position of about $1.04 billion. Operating cash flow was $69.5 million, while free cash flow reflected ongoing capital discipline. On the balance sheet, Veeva maintained a conservative leverage profile with total debt of ~$75.8 million and net debt of approximately -$1.043 billion, highlighting substantial liquidity to fund product investments and potential strategic opportunities.
Key drivers remain the continued adoption of Veeva’s Commercial Cloud and Vault platform across life sciences organizations, with a favorable mix toward subscription-based ARR and data-centric offerings. Management commentary (where available) points to steady demand and backlog in core modules, although explicit forward guidance was not disclosed in the provided materials. Investors should monitor revenue momentum in Vault/Data Cloud, ARR progression, international penetration, and any shifts in contract tenure as indicators of long-term durability.
Key Performance Indicators
Key Insights
Revenue: 720.886 million USD; YoY growth: 14.31%; QoQ growth: 3.10%
Gross Profit: 539.895 million USD; Gross Margin: 74.89%
Operating Income: 188.423 million USD; Operating Margin: 26.14%
EBITDA: 198.355 million USD; EBITDA Margin: 27.51%
Net Income: 195.625 million USD; Net Margin: 27.14%
EPS (GAAP): 1.20; EPS (Diluted): 1.18; Weighted Avg Shares (out): 162.391 million; Diluted: 165.674 million
Cash Flow: Net cash from operating activities 69.544 million USD; Capex (USD): 4.72 million; Free Cas...
Financial Highlights
Revenue: 720.886 million USD; YoY growth: 14.31%; QoQ growth: 3.10%
Gross Profit: 539.895 million USD; Gross Margin: 74.89%
Operating Income: 188.423 million USD; Operating Margin: 26.14%
EBITDA: 198.355 million USD; EBITDA Margin: 27.51%
Net Income: 195.625 million USD; Net Margin: 27.14%
EPS (GAAP): 1.20; EPS (Diluted): 1.18; Weighted Avg Shares (out): 162.391 million; Diluted: 165.674 million
Cash Flow: Net cash from operating activities 69.544 million USD; Capex (USD): 4.72 million; Free Cash Flow (reported): 69.544 million USD
Balance Sheet Highlights: Cash & equivalents 1.118B; Short-term investments 4.031B; Total cash & equivalents + investments ~5.15B; Total assets 7.340B; Total liabilities 1.508B; Shareholder equity 5.832B; Net debt = -$1.043B (net cash)
Liquidity & Efficiency: Current Ratio 4.51x; DSO ~132 days; Operating cash flow per share 0.419; Free cash flow per share 0.391; Price-to-book ~6.71x; Price-to-sales ~54.32x (as of QQ4 2025 data).
Income Statement
Metric |
Value |
YoY Change |
QoQ Change |
Revenue |
720.89M |
14.31% |
3.10% |
Gross Profit |
539.90M |
19.17% |
2.87% |
Operating Income |
188.42M |
39.30% |
3.90% |
Net Income |
195.63M |
32.72% |
5.28% |
EPS |
1.20 |
30.43% |
4.35% |
Key Financial Ratios
operatingProfitMargin
26.1%
operatingCashFlowPerShare
$0.42
freeCashFlowPerShare
$0.39
Management Commentary
Note: No earnings call transcript data was provided in the input. As a result, management quotes and thematic commentary from the QQ4 2025 earnings call could not be extracted.
Forward Guidance
No formal forward guidance was disclosed in the provided materials. Given the healthy quarterly trajectory and a favorable long-term growth pipeline for Veeva’s life sciences cloud platforms (Commercial Cloud, Vault, and Data Cloud), investors should monitor: (1) ARR growth and retention, (2) contribution mix between Commercial Cloud and Vault/Data Cloud, (3) international expansion momentum, (4) investment cadence in R&D and go-to-market initiatives, and (5) any changes in contract duration or large customer exposure that could affect revenue stability. In the absence of explicit guidance, the qualitative read is one of continued durable growth, subject to competitive dynamics and broader health-care IT spend cycles.